This page contains exclusive content for the member of the following sections: TTS, CTS, IPITA, ISODP, IXA, ITA, TID, IHCTAS, IPTA, SPLIT. Log in to view.
Presenter: Medhat, Askar, Dallas, TX, USA
Authors: Medhat Askar, Katherine Twombley
There are many new advances in the HLA world, and these technologies are developing at a rate faster than we know how to use them clinically. This session will examine the current evidence for and against epitope matching as well as review what is needed for future studies.
Katherine Twombley, MD, FAST, FAAP is a Professor in the Department of Pediatrics as well as the College of Graduate of Studies at the Medial University of South Carolina in Charleston, SC where she is also the Chief of Pediatric Nephrology and Medical Director of the Pediatric Kidney Transplant Program. She is on the Council for the International Pediatric Transplant Association (IPTA) and is Chair of the Education committee for IPTA. She is also the Co-Chair of the Executive Committee for the American Society of Transplantation’s Pediatric Community of Practice.
Medhat Askar, MD, PhD, MSHPE, FRCPath, D(ABHI), D(ABMLI), HCLD(ABB) is a Clinical Professor (Affiliated) in the Department of Pathology and Laboratory Medicine (affiliated) at Texas A&M Health Science Center College of Medicine and the director of the Transplant Immunology and facility director of the Cell Processing Laboratories at Baylor University Medical Center in Dallas, TX, USA. He is the President of The American Society for Histocompatibility and Immunogenetics (ASHI), the Immediate Past President of The American Board of Histocompatibility and Immunogenetics (ABHI). Dr. Askar is a Councilor (North America) and Co-Chair of the TTS Education Committee of The Transplantation Society (TTS). He is also a Member of Board of Directors of United Network for Organ Sharing (UNOS), Organ Procurement and Transplantation Network (OPTN) and a Member of The Joint Commission Pathology Technical Advisory Panel (JC-TAP).
By viewing the material on this site you understand and accept that: